Anatomy-based Fitting in Cochear Implant Users
Study Details
Study Description
Brief Summary
In this study, the performance with the CI is investigated over time in three groups of freshly implanted CI users. Both the standard frequency-band distribution and anatomy-based fitting will be used to compare outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
In this study, the performance with the CI is investigated over time in three groups of freshly implanted CI users. The first group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9. In the second group of users, an anatomy-based frequency distribution is used as per anatomy-based fitting in MAESTRO 9. The performance with anatomy-based fitting is assessed by comparing performance with the CI in these two groups over time.
The third group constitutes the within-subject design. These subjects are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Standard fitting The first group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9 |
Procedure: Standard Fitting
These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
|
| Experimental: Anatomy-based fitting In the second group of users, an anatomy-based frequency distribution is used as per anatomy-based fitting in MAESTRO 9 |
Procedure: Anatomy-based fitting (ABF)
MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
|
| Experimental: Within-subject design: Standard fitting + ABF The third group constitutes the within-subject design. These subjects are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. |
Procedure: Standard fitting+ ABF
Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
|
Outcome Measures
Primary Outcome Measures
- Result from the speech test in noise (S0N0) [Month 6]
Speech perception evaluation with CI-only (MATRIX) with signal and noise in the same channel
- Results from speech tests in noise with spatially separated loudspeakers [Month 6]
Speech perception evaluation with CI-only (MATRIX) with signal and noise in different channels
- Result from the speech test in quiet (S0) [Month 6]
Speech perception evaluation with CI-only (disyllables)
Secondary Outcome Measures
- Results of quality of sound [Month 6]
Subjective results through Hearing Implant Sound Quality Index 19. Scores range 19-133 points. Higher scores mean a better outcome.
- Results of quality of life in challenging situations [Month 6]
Subjective results through Listening effort questionnaire. Scores range 21-93 points. Higher scores mean a better outcome.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years
-
Post-lingual onset of severe to profound sensory-neural hearing loss in the implanted ear(s)
-
Post-OP CT scan of the CI electrode available
-
Subject implanted with MED-EL cochlear implant(s)
-
Subjects received a Flex28 or FlexSoft electrode
-
Subject planned to receive a SONNET 2 /RONDO3 audio processor on the newly implanted side
-
Audio processor not yet activated on the newly implanted side
-
The most apical active electrode contact has to be inserted at least 450°
-
Minimum of 10 active channels can be activated
-
Fluent in Spanish
-
Signed and dated ICF before the start of any study-specific procedure
Specific inclusion criteria for the possible study groups • Bilateral CI users: Bilateral CI implantation SONNET 2/RONDO3 audio processor on the first ear implanted
-
40% speech recognition a monosyllabic word Test in quiet at 65 dB SPL (last time tested) on the already implanted side
-
40% speech recognition in a sentence test in noise (10 dB SNR) on the already implanted side First activation of the already implanted side between 3 and 12 months prior to study inclusion
• Unilateral CI users: Unilateral CI implantation CI user with contralateral hearing ≥ 60 dB (PTA measured at 500, 1000, 2000, and 4000 Hz)
• SSD CI users: Unilateral CI implantation CI user with contralateral hearing ≤30 dB (PTA measured at 500, 1000, 2000, and 4000 Hz) Interaural threshold gap ≥40 dB
• Bimodal CI users: Unilateral CI implantation Contralateral ear adequately fitted with a hearing aid CI user with contralateral hearing ≥30 dB (PTA measured at 500, 1000, 2000, and 4000 Hz) CI user with contralateral hearing ≤55 dB (PTA measured at 500, 1000, 2000, and 4000 Hz) Interaural threshold gap ≥15 dB
Exclusion Criteria:
-
Lack of compliance with any inclusion criteria
-
EAS user (user of an EAS audio processor)
-
Implanted with C40+, C40X and C40C
-
Implanted with an ABI or Split electrode array
-
Known allergic reactions to components of the investigational medical device
-
Anything that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Universitario de La Paz | Madrid | Spain | 28046 |
Sponsors and Collaborators
- Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
- MED-EL Elektromedizinische Geräte GesmbH
Investigators
- Principal Investigator: Luis Lassaletta, PhD, Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PI-6128